Racecadotril for acute diarrhoea in children: systematic review and meta-analyses
Morris Gordon1, Anthony Akobeng2
1Department of Medical Education, Blackpool Victoria Hospital, Blackpool, UK School of Medicine and Dentistry, University of Central Lancashire, Preston, UK.
Insights
Racecadotril effectively reduces acute diarrhea duration in children compared to placebo. While generally safe, the evidence quality is limited by study biases and data scarcity.
Area of Science:
- Gastroenterology
- Pediatrics
- Pharmacology
Background:
- Acute diarrhea is a common childhood illness causing fluid and electrolyte depletion.
- Racecadotril is an antisecretory agent that reduces intestinal fluid secretion without altering motility.
- A systematic review is needed to evaluate racecadotril's efficacy and safety in pediatric acute diarrhea.
Purpose of the Study:
- To systematically review randomized controlled trials (RCTs) on racecadotril for acute diarrhea in children.
- To assess the impact of racecadotril on illness duration, stool output, and adverse events.
- To evaluate the overall quality of evidence for racecadotril in pediatric diarrhea treatment.
Main Methods:
- A systematic review following Cochrane guidelines.
- Inclusion of RCTs comparing racecadotril with placebo or other treatments in children with acute diarrhea.
- Independent data extraction and risk of bias assessment using the Cochrane risk of bias tool.
Main Results:
- Seven RCTs were included; five compared racecadotril with placebo.
- Meta-analysis showed racecadotril significantly reduced symptom duration compared to placebo (mean difference -53.48 hours).
- No significant difference in adverse events was found between racecadotril and placebo, or between racecadotril and loperamide.
Conclusions:
- Racecadotril demonstrates effectiveness in reducing illness duration and stool output in pediatric acute diarrhea.
- The overall evidence quality is limited by data heterogeneity and risk of bias in included studies.
- Racecadotril is considered safe and well-tolerated for treating acute diarrhea in children.
Objective:
Racecadotril is an antisecretory agent that can prevent fluid/electrolyte depletion from the bowel as a result of acute diarrhoea without affecting intestinal motility. An up-to-date systematic review is indicated to summarise the evidence on racecadotril for the treatment of acute diarrhoea in children.
Design:
A Cochrane format systematic review of randomised controlled trials (RCTs). Data extraction and assessment of methodological quality were performed independently by two reviewers. Methodological quality was assessed using the Cochrane risk of bias tool.
Patients:
Children with acute diarrhoea, as defined by the primary studies.
Interventions:
RCTs comparing racecadotril with placebo or other interventions.
Main Outcome Measurs:
Duration of illness, stool output/volume and adverse events.
Results:
Seven RCTs were included, five comparing racecadotril with placebo or no intervention, one with pectin/kaolin and one with loperamide. Moderate to high risk of bias was present in all studies. There was no significant difference in efficacy or adverse events between racecadotril and loperamide. A meta-analysis of three studies with 642 participants showed significantly shorter duration of symptoms with racecadotril compared with placebo (mean difference -53.48 h, 95% CI -65.64 to -41.33). A meta-analysis of five studies with 949 participants showed no significant difference in adverse events between racecadotril and placebo (risk ratio 0.99, 95% CI 0.73 to 1.34).
Conclusions:
There is some evidence that racecadotril is more effective than placebo or no intervention in reducing the duration of illness and stool output in children with acute diarrhoea. However, the overall quality of the evidence is limited due to sparse data, heterogeneity and risk of bias. Racecadotril appears to be safe and well tolerated.
Related Concept Videos
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption